How to make cell and gene therapies affordable

Published 4 Min Read

Adobe Stock

  • Key Insight: Discover how pooled stop-loss models are reshaping employer exposure to multimillion-dollar CGT claims.
  • What’s at Stake: Single $4M claim can spike premiums, destabilize self-funded plans.
  • Forward Look: Expect growing CGT approvals; unit costs may decline but volatility persists.

Source: Bullets generated by AI with editorial review

Bruce Shutan
Contributing writer

Bruce Shutan is an Employee Benefit News contributing writer based in Portland, Oregon.


For reprint and licensing requests for this article, click here.


More From Employee Benefit News

Sign Up Form

Login Modal Form